Evidence map›Paper›PMID 33605563›Full record

ArticleACR open rheumatology2021

A Panel of Biomarkers Associates With Increased Risk for Cardiovascular Events in Women With Systemic Lupus Erythematosus.

Brian J Skaggs, Jennifer Grossman, Lori Sahakian, Lucas Perry, John FitzGerald, Christina Charles-Schoeman, Alan Gorn, Mihaela Taylor, John Moriarty, Nagesh Ragavendra and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACR open rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Vascular damage in systemic lupus erythematosus.Nature reviews. Nephrology · 2024
    Review
  9. Review
  10. CXInflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Cardiovascular disease in systemic lupus erythematosus.Rheumatology and immunology research · 2021
    Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Brian J SkaggsUniversity of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA.
Jennifer GrossmanUniversity of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA.
Lori SahakianUniversity of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA.
Lucas PerryUniversity of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA.
John FitzGeraldUniversity of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA.ORCID https://orcid.org/0000-0002-8419-7538
Christina Charles-SchoemanUniversity of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA.
Alan GornUniversity of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA.
Mihaela TaylorUniversity of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA.
John MoriartyUniversity of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA.
Nagesh RagavendraUniversity of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA.
Michael WeismanCedars Sinai Medical Center, Los Angeles, California.ORCID https://orcid.org/0000-0001-5568-388X
Daniel J WallaceUniversity of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA.ORCID https://orcid.org/0000-0002-2502-1372
Bevra H HahnUniversity of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA.
Maureen McMahonUniversity of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA.ORCID https://orcid.org/0000-0002-2910-7640
University of California, Los Angeles · USCedars-Sinai Medical Center · US

Funding

The PREDICTS risk score for increased atherosclerosis and disease activity in SLER01AR063754 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCMAHON, MAUREEN A · 2014 to 2018
$2.8M
The Role of Monocytes in SLE-related Accelerated AtherosclerosisK01AR059095 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SKAGGS, BRIAN J · 2010 to 2014
$695k
Lupus Research AllianceNIAMS NIH HHS K01 AR059095NIAMS NIH HHS K01AR059095NIAMS NIH HHS R01 AR063754NIAMS NIH HHS R01AR063754-01A1
6 · The paper itself

Abstract

objectiveThe increase in cardiovascular events (CVEs) in systemic lupus erythematosus (SLE) is not fully explained by traditional risk factors. We previously identified four biomarkers (proinflammatory high-density lipoprotein, leptin, soluble TNF-like weak inducer of apoptosis (sTWEAK), and homocysteine) that we combined with age and diabetes to create the predictors of risk for elevated flares, damage progression, and increased cardiovascular diseasein patients with SLE (PREDICTS) risk profile. PREDICTS more accurately identified patients with SLE at risk for progression of subclinical atherosclerosis than any individual variable. We examined whether PREDICTS can also identify patients with SLE at risk for future CVEs.

methodsA total of 342 patients with SLE and 155 matched control subjects participated in this longitudinal prospective study. A high PREDICTS score was defined as three or more predictors or diabetes + one or more predictor. The biomarkers were measured at baseline using published methods. All major adverse CVEs (MACEs) were confirmed by medical record review.

resultsDuring 116 months of follow-up, 5% of patients with SLE died, 12% had a cerebrovascular event, and 5% had a cardiac event. Overall, 20% of patients with lupus experienced any new MACE compared with 5% of control subjects (P < 0.0001). More patients with SLE with a new MACE had high PREDICTS score at baseline (77%) versus patients with no new events (34%) (P < 0.0001). High baseline PREDICTS score also associated with cerebrovascular (P < 0.0001) and cardiac events (P < 0.0001) in SLE. Using Cox regression, a baseline high PREDICTS score associated with a 3.7-fold increased hazard ratio (HR) for a new MACE (P < 0.0001) in SLE. Hypertension (HR = 2.1; P = 0.006) was also a risk.

conclusionA high PREDICTS score and hypertension confer increased risk for new MACEs in patients with SLE.

Identifiers

PMID33605563
PMCPMC8063147
OpenAlexW3131615341

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.